Search | Page 3 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Engraftment of heavily transfused patients with severe aplastic anemia with a fludarabine-based regimen

    ... in total, 77 patients showed durable engraftment and transfusion independence , and 64 are alive at a median time of 49 months with an ...

    Research Article last updated 07/20/2018 - 5:15pm.

  2. Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies

    ... leading to hemoglobin stabilization and transfusion independence in more than half of the patients. However, recent ...

    Research Article last updated 07/20/2018 - 5:15pm.

  3. Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies

    ... leading to hemoglobin stabilization and transfusion independence in more than half of the patients. However, recent ...

    Research Article last updated 07/20/2018 - 5:14pm.

  4. Long term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival.

    ... (66%) patients on treatment for over 12 months achieved transfusion independence on eculizumab. The mean transfusion requirement reduced by ...

    Research Article last updated 07/20/2018 - 5:14pm.

  5. p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q)

    ... but not with achievement or duration of 26-week transfusion independence response. In a multivariate analysis, p53-positive ...

    Research Article last updated 07/20/2018 - 5:15pm.

  6. Early treatment initiation in lower-risk myelodysplastic syndromes produces an earlier and higher rate of transfusion independence

    ... transfusions can improve anemia ; however, prolonged transfusion dependence (TD) is associated with increased morbidity and ... start of TD) on the likelihood of achieving transfusion independence (TI) among 508 TD patients with MDS. Mean time to DMT was ...

    Research Article last updated 09/13/2017 - 8:58am.

  7. Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes

    ... remission, red blood cell [RBC] or platelet transfusion independence [TI], or hematologic improvement, (IWG 2006) was attained by 36% ...

    Research Article last updated 07/20/2018 - 5:15pm.

  8. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia

    ... remission, hematologic improvement, or RBC or platelet transfusion independence) was 35% in previously treated patients and 73% in previously ...

    Research Article last updated 07/20/2018 - 5:14pm.

  9. Patterns of treatment and costs associated with transfusion burden in patients with myelodysplastic syndromes.

    ... Transfusion dependence (TD) among myelodysplastic syndromes (MDS) ... cost patterns of MDS care during TD and transfusion independence (TI). MDS patients were identified from a US claims database ...

    Research Article last updated 05/22/2017 - 11:01am.

  10. Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes

    ... is approved for the treatment of patients who have transfusion-dependent anemia due to lower-risk MDS with chromosome 5q ... clinical benefits included high rates of RBC-transfusion independence (TI) with prolonged durations of response, high rates of ...

    Research Article last updated 07/20/2018 - 5:15pm.